US 11,859,189 B2
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
Dylan Alexander Carlin, Jamaica Plain, MA (US); Vincent M. Isabella, Medford, MA (US); Jonathan McMurry, Boston, MA (US); Theodore Carlton Moore, III, Cambridge, MA (US); Mylene Perreault, Lexington, MA (US); Nathan Schmidt, Milton, MA (US); and Mark Simon, Gainesville, FL (US)
Assigned to Synlogic Operating Company, Inc., Cambridge, MA (US); and Ginkgo Bioworks, Inc., Boston, MA (US)
Filed by Synlogic Operating Company, Inc., Cambridge, MA (US); and Ginkgo Bioworks, Inc., Boston, MA (US)
Filed on Aug. 11, 2022, as Appl. No. 17/819,086.
Claims priority of provisional application 63/231,773, filed on Aug. 11, 2021.
Claims priority of provisional application 63/281,178, filed on Nov. 19, 2021.
Claims priority of provisional application 63/282,319, filed on Nov. 23, 2021.
Claims priority of provisional application 63/326,323, filed on Apr. 1, 2022.
Claims priority of provisional application 63/355,819, filed on Jun. 27, 2022.
Prior Publication US 2023/0063093 A1, Mar. 2, 2023
Int. Cl. C12N 9/88 (2006.01); C12N 15/52 (2006.01); A61K 35/741 (2015.01); C12N 15/70 (2006.01); C07K 14/245 (2006.01)
CPC C12N 15/52 (2013.01) [A61K 35/741 (2013.01); C07K 14/245 (2013.01); C12N 9/88 (2013.01); C12N 15/70 (2013.01); C12Y 401/01057 (2013.01); C12Y 404/01011 (2013.01)] 14 Claims
 
1. A recombinant bacterial cell comprising:
a heterologous methionine decarboxylase (metDC) gene operably linked to a promoter, wherein the heterologous metDC gene encodes a polypeptide comprising SEQ ID NO: 1048.